This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

15 Jul 2011

Advaxis Concludes Patient Enrolment in Neoplasia Study

Advaxis has concluded patient recruitment in first low dose cohort in a Phase II trial.

Advaxis, a biotechnology company focused on cancer vaccines, has concluded enrolment of the first 40-subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for cervical intraepithelial neoplasia.


The randomised, single blind, placebo-controlled Phase II study is designed to evaluate the drug's safety and efficacy in up to three dose cohorts.


Advaxis chairman and CEO Thomas Moore said that the six-month follow-up evaluation for this first cohort will be completed by January 2012, and the low dose results are expected to be released in early 2012.

Related News